SC 13D/A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
13d-1(a) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(a)

Under the Securities Exchange Act of 1934
(Amendment No. 1 )

BIOLASE TECHNOLOGY, INC.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

090911108

(CUSIP Number)

Federico Pignatelli
Pier 59 Studios
Pier 59
Chelsea Pier
New York, NY 10011
(917) 960-3200

Copies to:
Bruce D. Meyer
Gibson, Dunn & Crutcher LLP
333 South Grand Avenue
Los Angeles, CA 90071
(213) 229-7979

(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)

June 4, 2010

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. o

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 090911108 

1.	Names of Reporting Persons Federico Pignatelli
2.	Check the Appropriate Box if a Member of a Group (See Instructions)
	(a)   o
	(b)   o
3.	SEC Use Only
4.	Source of Funds (See Instructions)
	PF
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   o
	N/A
6.	Citizenship or Place of Organization
	United States
		7.	Sole Voting Power
Number of			1,345,250
Shares		8.	Shared Voting Power
Beneficially
Owned by			0
Each		9.	Sole Dispositive Power
Reporting
Person			1,345,250
With		10.	Shared Dispositive Power
			0
11.	Aggregate Amount Beneficially Owned by Each Reporting Person
	1,345,250
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)    o
	N/A
13.	Percent of Class Represented by Amount in Row (11)
	5.4%1
14.	Type of Reporting Person (See Instructions)
	IN

¹ Based upon 24,388,778 shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 17, 2010.

     This Amendment No. 1 (this “Amendment”) amends and supplements the Schedule 13D filed on May 17, 2010 (the “Original Filing”) by the Reporting Persons relating to the common stock, par value $0.001 per share (“Common Stock”) of Biolase Technology, Inc., a Delaware corporation (the “Issuer”). Information reported in the Original Filing remains in effect except to the extent that it is amended, supplemented, restated or superseded by information contained in this Amendment. Capitalized terms used but not defined in this Amendment have the respective meanings set forth in the Original Filing.

Item 1. Security and Issuer.

Item 1 is hereby amended and restated as follows:

     This Amendment, which relates to the Reporting Person’s beneficial ownership of the Issuer’s Common Stock, is being filed to supplement the disclosure in Item 4 of the Original Filing and amend Item 7 of the Original Filing. The principal executive offices of the Issuer are located at 4 Cromwell, Irvine, California 92618.

Item 4. Purpose of Transaction.

Item 4 of the Original Filing is hereby supplemented as follows:

     In response to the Reporting Person’s continued dissatisfaction with the performance of the Board of Directors of the Issuer, on June 4, 2010, the Reporting Person delivered a letter, which the Reporting Person modified and re-delivered on June 7, 2010 (as modified, the “Letter”) to the Secretary of the Issuer (and a copy to each member of the Board of Directors of the Issuer), notifying the Secretary that in the Reporting Person’s capacity as President of the Issuer, the Reporting Person was exercising his right pursuant to Section 2.3(a) of the Issuer’s Bylaws, to call a special meeting (the “Meeting”) of the Issuer’s stockholders on August 6, 2010, at 11AM Pacific Daylight Time, at the Issuer’s Corporate offices. Pursuant to the Letter, the Reporting Person proposed that at the Meeting, the Issuer’s stockholders vote to (i) remove all persons serving as directors of the Issuer at the Meeting, other than himself and Mr. David M. Mulder; (ii) amend Section 3.2 of the Bylaws to reduce the size of the Board to no less than three directors and no more than seven directors; (iii) amend Section 3.4 of the Bylaws to require the unanimous vote of all remaining members of the Board to fill any vacancy on the Board whether as a result of an increase in the authorized number of directors on the Board or otherwise; (iv) amend Section 4.6 of the Bylaws to provide that the Board must adhere to any voting requirements required by the Bylaws; (v) amend Sections 7.1 of the Bylaws to require that (a) the Chief Executive Officer (the “CEO”) and Chief Financial Officer (or the principal officer having responsibility for financial matters pertaining to the Issuer) (the “CFO”) be elected by the unanimous vote of all directors other than any director who is being considered for election as the CEO or CFO, as applicable, by the Board, and (b) the Chairman of the Board be elected by the affirmative vote of all directors on the Board but one director; provided, however that the CEO may not serve as Chairman of the Board unless he/she is elected by the unanimous vote of all directors on the Board; (vi) add a new Section 9.11 to the Bylaws requiring the unanimous vote of all members of the Board to issue Issuer securities except as specifically provided for therein; and (vii) amend Section 11.2 of the Bylaws to require unanimous Board approval (or stockholder approval) to amend or repeal Sections 2.9, 3.2, 3.4, 4.6, 7.1, and 9.11 of the Bylaws. The Reporting Person intends to file a proxy statement with the United States Securities and Exchange Commission relating to the Meeting and to solicit proxies in support of the foregoing proposals. The Reporting Person believes that such changes in the Issuer’s Board of Directors and the Issuer’s Bylaws is in the best interests of the Issuer’s stockholders and could help maximize stockholder value.

     A copy of the Letter is filed herewith and attached hereto as Exhibit 1 and is incorporated by reference herein. The description of the Letter is qualified it its entirety by reference to the attached Exhibit 1.

Item 7. Material to Be Filed as Exhibits.

Item 7 is hereby amended and restated as follows:

     Exhibit 1 — Letter to Secretary of Biolase Technology, Inc., dated June 7, 2010.

SIGNATURE

     After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

/s/ Federico Pignatelli	June 8, 2010
Federico Pignatelli

EX-99.1

Exhibit 1

June 7, 2010

DELIVERED BY HAND AND BY U.S. MAIL, RETURN RECEIPT REQUESTED

Secretary
BIOLASE Technology, Inc.
4 Cromwell
Irvine, CA 92618

Re: Notice of Call of Special Meeting of Stockholders

Dear Mr. Mulder:

I am the duly elected and acting President of BIOLASE Technology, Inc., a Delaware corporation (the “Company”), and pursuant to Section 2.3(a) of the Fourth Amended and Restated Bylaws of the Company (the “Bylaws”) and this letter, I am hereby calling a special meeting of stockholders of the Company (the “Special Meeting”) to be held at 11 AM Pacific Daylight Time on August 6, 2010 (the “Meeting Time”) at the Company’s corporate headquarters, located at 4 Cromwell, Irvine, CA 92618, solely for the following purposes:

1. The removal of all persons serving as directors of the Company at the Meeting Time (other than Federico Pignatelli and David M. Mulder), including without limitation:

George V. d’Arbeloff
Robert M Anderton
James R. Largent
Gregory D. Waller

2. Amend Section 3.2 of the Bylaws in its entirety to read as follows (marked to show changes):

Section 3.2 Number.

     The number of directors which shall constitute the whole Board shall be fixed from time to time by the resolution of the Board. In no event shall the total number of directors which shall constitute the whole Board be fixed by the Board at less than three (3) or more than nineseven (97). With the exception of the initial Board which shall be elected by the incorporator of the Corporation, and except as provided otherwise in these Bylaws, directors shall be elected at, the annual meeting of stockholders. Each director shall hold office until the earlier to occur of (a) the annual meeting of stockholders next succeeding his or her election or appointment and untilthe election and qualification of his or her successor is elected and qualified or until or (b) his or her earlier resignation or removal.

3. Amend Section 3.4 of the Bylaws in its entirety to read as follows (marked to show changes):

Section 3.4 Vacancies and Newly Created Directorships.

     Vacancies occurring for any reason and newly-created directorships resulting from an increase in the authorized number of directors which shall constitute the whole Board, as fixed pursuant to Section 3.2 of these Bylaws, shall be filled by the election of a new director or directors by a majoritythe unanimous vote of theall remaining members of the Board, although such majority isthe remaining directors may be less than a quorum, or by the required vote set forth in Section 2.9 at an Election Meeting. Any director so chosen shall hold office until the earlier of (a) the annual meeting of stockholders next succeeding his or her election or appointment and untilthe election and qualification of his or her successor shall be elected and qualified, or untilor (b) his or her earlier resignation or removal.

4. Amend Section 4.6 of the Bylaws in its entirety to read as follows (marked to show changes):

Section 4.6 Required Vote.

     Except as specifically provided otherwise by the General Corporation Law of the State of Delaware, these Bylaws or the Certificate of Incorporation, the affirmative vote of a majority of the directors present at a meeting of the Board at which a quorum is present shall be the act of the Board with respect to the matter voted upon.

5. Amend Section 7.1 of the Bylaws in its entirety to read as follows (marked to show changes):

Section 7.1 Officers.

     At its annual meeting, or at such other meeting as it may determine, or by unanimous written consent of the directors without meeting, the Board shall elect such officers as the Board from time to time may designate or the business of the Corporation may require. The CEO and Chief Financial Officer (or the principal officer having responsibility for financial matters pertaining to the Corporation) (the “CFO”) must be elected by the unanimous vote of all directors other than any director who is being considered for election as the CEO or CFO, as applicable, by the Board. The Chairman of the Board shall be selected from among the directors on the Board, but no and must be elected by the affirmative vote of all directors on the Board, but one director; provided, however, that the CEO may not serve as Chairman of the Board unless he/she is elected by the unanimous vote of all directors on the Board. No other executive officer need be a member of the Board. Any number of offices may be held by the same person.

6. Add a new Section 9.11 to the Bylaws to read as follows:

Section 9.11 Security Issuances.

     The Corporation may only offer, sell or issue, or contract to offer, sell or issue shares of its common stock, preferred stock, or any securities convertible into or exchangeable or exercisable for shares of its common stock or preferred stock upon the unanimous vote of all members of the Board except for the following: (a) grants of stock options, stock appreciation rights, restricted stock, restricted stock units or other stock-based awards pursuant to any equity compensation plan approved by the Corporation’s stockholders; (b) issuances of shares of common stock or preferred stock pursuant to the exercise, conversion or vesting of stock options, stock appreciation rights, restricted stock, restricted stock units or other stock-based awards granted pursuant to any equity compensation plan approved by the Corporation’s stockholders; (c) any sales or issuances, or contracts to sell or issue shares, of common stock, which on the date of sale or issuance or such contract, when combined with any sales or issuances, or contracts to sell or issue shares, of common stock in the preceding twelve month period, amounts to less than 10% of the Corporation’s outstanding common stock on the date of sale, issuance or contract; (d) issuances of securities of the Corporation in accordance with the terms of that certain Rights Agreement dated as of December 31, 1998, between the Corporation and U.S. Stock Transfer Corporation, as amended through June 1, 2010; and (e) issuances of shares of common stock pursuant to the exercise of warrants outstanding on June 7, 2010 that provide for the issuance of up to 101,694 shares of common stock and that were granted to MidCap Financial, LLC and Silicon Valley Bank pursuant to that certain Loan and Security Agreement dated as of May 27, 2010.

7. Amend Section 11.2 of the Bylaws in its entirety to read as follows (marked to show changes):

Section 11.2 By the Board.

     These Bylaws may be amended or repealed in whole or in part and new Bylaws may be adopted by a majority of the Board as provided by Section 109(a) of the General Corporation Law of the State of Delaware and the Certificate of Incorporation; provided, however, that Section 2.9Sections 2.9, 3.2, 3.4, 4.6, 7.1, and 9.11 may be amended or repealed in whole or in part only by the affirmative vote of at least five independent directors (as determined in accordance with applicable Nasdaq rules and listing requirements); and provided further, that if at the time of such action the Board consists of less than five independent directors, Section 2.9 may be amended only by a unanimous vote of the Boardunanimous vote of all members of the Board (or by the Corporation’s stockholders in accordance with Section 11.1).

I hereby establish that record date for stockholders of record who are entitled to notice of and to vote at the Special Meeting and any adjournment or postponement thereof shall be as of the close of business on June 7, 2010 (the “Record Date”).

In accordance with Section 2.4 of the Bylaws, you are hereby directed to promptly (but in any event not later than June 9, 2010) provide notice of the calling of this Special Meeting to all stockholders of record as of the Record Date. In addition, you are hereby directed to promptly (but in any event not later than June 9, 2010) provide me with a complete list of stockholders as of the Record Date, showing the address and phone number of each such stockholder and the number of shares of stock of the Company registered in the name of each such stockholder.

Very truly yours,

/s/ Federico Pignatelli

Federico Pignatelli
President
BIOLASE Technology, Inc.

cc: George V. d’Arbeloff
Robert M Anderton
James R. Largent
Gregory D. Waller
Bill Cernius
Michael Carroll